Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, M. Beylot‐Barry et al.|European Journal of Cancer|2021Cited by 93
Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the LiteratureManon De Vries-Brilland, Marine Gross‐Goupil, Alain Ravaud et al.|Clinical Genitourinary Cancer|2019Cited by 12
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational studyAlexandra Ladouceur, Marie Kostine, Mathieu Larroquette et al.|RMD Open|2023Cited by 9
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational studyAlexandra Ladouceur, Marie Kostine, M. Beylot‐Barry et al.|Joint Bone Spine|2024Cited by 5
Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitorsE. Gefard-Gontier, Marie Kostine, M. Beylot‐Barry et al.|Cancer Immunology Immunotherapy|2022Cited by 3